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ABSTRACT
Eight organo-iron ferrocene derivatives and arenocenium salts were prepared and evaluated by "in
vitro" assay against one strain of T.rypanosoma cruzi (Y). Six of the eight organo-iron compounds assayed,
piperazinium diferrocenoate 1, rl6-(o-xylene)-rls-(cyclopentadienyl). Iron(II) hexafluorophosphate 3, rl6-
(mesitylene)-rl-(cyclopentadienyl) iron(II)hexafluorphosphate 5, rl-(durene)-rlS-(eyclopentadienyl) iron(II)
hexafluorphosphate 6, rl6-(p-chlorotoluene)-ls-(cyclopentadienyl) Iron(II) hexafluorphosphate 7 and rl6-
(chlorobenzene)-ls-(cyclopentadienyl) iron(II) picrate $, were poorly active in the "in vitro’’ assays. Only
two compounds 1,1’-(N-pyperidinocarbonyl) ferrocene 2 (IC50=2.4 tg/mL) and rl-(o-xylene)-l-
(cyclopentadienyl) iron(II) picrate 4 (IC50=12.08 lxg/mL), were more active. Thus, some of the compounds are
promising to be used against Chagas’ disease as a prophylactic agents.
INTRODUCTION
The therapeutic use of metals or inorganics salts is secular. Paracelso (in 1700), preconized
the use of the minerals and iron, cadmium, mercury, arsenic, gold and antimony salts as medicine
("Iatrochemistry") in oposite to the vitalist hypothesis ("Vital Force") accepted at that time.
The rational use of metals, semi-metals and their compounds in therapeutic started with Lissauer in
1865 who administered a topic antiseptic, an arsenical formulation called "Fowler Licor", to the
leucemics patients. Therefore, the use of metals in the therapeutics had a greatest increase, as an
example, the use of cacodilates and cacodil oxides (alquil arseniates) and injections of coloidals
arsenic, silver, gold and antimony in oncology chemotherapy.
Relegated to a second plane, the new metal drug researchs practically stopped until the
discovery of the use of cisdiaminedichoroplatinum(II) comlglex (Cisplatin(R)) with bactericidal,
cytostatic and antineoplastic properties, by Rosenberg in 1969’.
Among the few developed potencial organo-iron drugs’, in recent years ferrocene based
anti-malarial agents have been described and the ferrocene analogs of chloroquine, mefloquine and
quinine have been tested46.
Silva et al. in 19997, reported a significative analgesic effect produced by rl6-(anisole)
triscarbonyl chromium(0), a chromium derivative complex.
Chagas’ disease was characterized in the Americas in 1909s. Since this time, not much
progress has been achieved for controlling this serious illness. This is in part because of the high
interaction between the parasite and its hosts. Today, fewer drugs are used against Chagas’ disease.
Therefore, these drugs were showed to be efficient over time.
The aim of this work was the synthesis of some organo-iron compounds and their
trypanocidal evaluation, attempting to discover a new drug class against Chagas’ disease.
MATERIALS AND METHODS
Experimental
Piperazinium diferrocenoate 1 and 1,1’-(N-piperidinocarbonyl)ferrocene 2, were prepared as
previously published9.
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Fully experimental details, apparatus and assembly for the improved ligand exchange reaction in
ferrocene, under microwave irradiation conditions, were recently submitted for publication. All the
arenocenium salts used in this work: rl6-(o-xylene)-rls-(cyclopentadienyl) iron(lI) hexafluorophosphate 3, rl6-
(o-xylene)-rls-(cyclopentadienvl) Iron(II) picrate 4, rl6-(mesitylene)-rls-(cyclopentadienyl) iron(II)
hexafluorphosphate 5, rl6"-(durene)-rlS-(cyclopentadienyl) Iron(II) hexafluorophosphate 6, rl6-(o-
chlorotoluene)-rl5-(cyclopentadienyl) iron(II) hexafluorophosphate 7 and rl6-(chlorobenzene)-rl-
(cyclopentadienyl) iron(II) picrate 8 were prepared by a further modification
3 of this procedure. We found
that the aluminum metal powder may be substituted by zinc powder with equivalent results and a teflon
beaker may be used, instead ofthe Berzelius flask (tall beaker), avoiding any risk ofglassware breakage.
Strain of Trypanosoma cruzi
The compounds were tested against the strain Y of T.cruzi. The Y strain shows predominantly
slender blood trypomastigote forms with macrophage tropism and is characterized in phylogenetic lineage I
and the Trypanosoma cruzi II group.
In vitro Bioassay
The bioassays were carried out using blood of infected Swiss albino mice, collected by cardiac
puncture at the peak of the parasitemic infection (7
th day of infection for Y strain). The infected blood was
diluted to achieve a concentration of 106 trypomastigote forms/mL. The solutions of the compounds were
prepared in DMSO and were added into the infected mouse blood to provide concentrations of 100, :250 and
500 lm/mL, respectively. The bioassays were performed in triplicate on microtiter plates (96 walls), which
contained 200 L of mixture for wall. The plates were incubated at 4 C for 24 hours under constant stirring.
Afterwards, the trypanocidal activity was evaluated by counting the trypomastigote forms of the parasite
remaining, following the method described by Brener2. Controls containing either DMSO or gentian violet at
250 g/mL were processed in parallel.
RESULTS AND DISCUSSION
The relative low toxicity of the ferrocene group 13, and their well established aromatic
character13, similar to the benzene group, as well the electron aceptor properties of the metal ligand
moieties7, makes ferrocene and other metal-ligand groups attractive for the use in drug design.
We prepared some organo-iron compounds, ferrocene derivatives (1 and 2) and
arenocenium salts (3-8) (Figure 1) and screened then for tripanocidal activity.
FIGURE 1. CHEMICAL STRUCTURES OF THE COMPOUNDS TESTED
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4 ortho xylene (R=methyl; R’=2-methyl) picrate
5 mesitylene (R=methyl; R’=3,5-dimethyl) PF6
6 durene (R=methyl; R’=2,3,4-dimethyl) PF6-
7 p-chlorotoluene (R=methyl; R’--C1)
8 chlorobenzene (R=H; R’=C1) PF6-
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The arenocenium salts were prepared by a modification of the recently submitted
procedure for the ligand exchange reaction of ferrocene and arenes, induced by microwave
irradiation.
During the application of this procedure to the synthesis of the tarzet compounds used in
this work, we discovered that the anti-economical excess of ferrocene, used in the original
procedure of Dabirmanesh et al.
5 is not necessary, and a large excess of the aluminum trichloride
as catalyst increase the yields, similarly to that we observed
5 with the old thermal induced
procedure for ferrocene ligand exchange.
Also, Astruc et al.
16 reported that the ligand exchange was a non-quantitative reaction, and
large amounts of unreacted ferrocene remain unchanged. We verified that in microwave conditions,
the ligand exchange reaction is quantitative with respect of the ferrocene amount. In the original
procedure, Dabirmanesh et al. could not observed the same results, because they carried out the
reactions ever in the presence of large excess of ferrocene.
It seems to us that due to the high caoacity of ionization of the microwaves, which may
increase the speed of many chemical reactions5, in these conditions, ferrocene can be very easily
cleaved for the efficient formation of the cyclopentadienyl iron(II) cation7’8, the reactive
intermediate ofthe ligand exchange reaction.
Table ! shows the results of T. cruzi biological assays. We can observe that all compounds
evaluated did not present very high activity against the parasite. However, we can see a high
therapeutic potential, by the significant results found in the evaluation, in the compounds 2 and 4,
that shown low IC50 values (2,4 and 12,08 lag/mL, respectively). In spite of these compounds not
showing a high activity against the parasites (57 % and 69 % of lysis), the results are very
interesting, mainly because they are practically insoluble in the protocol used for the trypanocidal
activity evaluation.
TABLE I. 1N VITROa’b TRYPANOCIDAL OfORGANO-IRON COMPOUNDS AGAINST Y STRAIN Of
T. cruzi.
Compounds
Trylanocidal activity (lise %’ +/-SD)
100
44.0 +/- 3
55.0+/-6
29.0 +/- 4
61.3 +/-3
50.0 +/- 8
44.5 +/- 5
48.2 +/-2
28.3 +/-3
Dose ([ag/mL)-Y strain
250
69.0 +/- 0
55.0+/-5
63.4 +_.2
65.0 __. 5
61.0+_.5
49.0 +/- 5
59.0+/-3
56.0__.0
5OO
79.0 +/- 3
57.0 +/- 9
73.3 +/- 4
69.0 _
7
62.0+/- 6
67.0 +/- 3
65.4 _
3
59.2 _
3
g/mL
124.0
2.40
189.3
12.08
89.95
80.08
116.8
257.6
Pb’itive controi"’," g. ntian violet, concent’ration of 250 g/mL (100 %’"’iysi) IC50 76 g/mL.
Negative controls. Mice infected blood without any added compound and mice blood infected
containing the same DMSO concentration used in the stock solutions, have not showed any
reduction of the parasite numbers.
We should point out the polymorphism existent among the trypomastigote forms of the
same lineage of T.cruzi that can present a difference in the susceptibility of the parasite in relation
to the evaluated compounds. We do not have an explanation for this, but it’s known that the
evolution of T.cruzi depends on several biological and genetic factors, inherent to the development
ofthe parasite, hindering the Chagas’ disease therapeutics.
Although the partial effectiveness for the trypanocidal activity, it opens a pathway for the
synthesis of other new derivatives and we may could evaluate the correlation between the chemical
structure and the type of biological activity, characteristic for this class ofcompounds.
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